精装
专利生物技术创新
资格，道德和公共利益
9781800884403 Edward Elgar Publishing
This book examines patent law and policy in biotechnology across the full lifecycle of the patent, focusing on the patent bargain and the public interest. It considers the central issues of how to strike an effective balance of rights, and whether public interest is adequately safeguarded - two issues that are particularly important in areas of rapidly emerging technology.
更多信息
Critical Acclaim
贡献者
内容
更多信息
This book examines patent law and policy in biotechnology across the full lifecycle of the patent, focusing on the patent bargain and the public interest. It considers the central issues of how to strike an effective balance of rights, and whether public interest is adequately safeguarded - two issues that are particularly important in areas of rapidly emerging technology.
专家贡献者聚集在一起，以探索生物技术中的专利资格，重点是精确医学领域，生物制造和非侵入性产前测试。章节还探讨了专利性的异常的构建和连贯性，在医学事物互联网背景下对FRAND许可的检查以及使用许可来鼓励或确保获得专利技术的道德使用的可能性。
通过精心构建的分析，本书将成为学术研究人员和学生在生物技术法，制药法和知识产权法领域的绝佳资源。这对于法律从业者和政策制定者以及慈善机构和非政府组织也将很有用。
专家贡献者聚集在一起，以探索生物技术中的专利资格，重点是精确医学领域，生物制造和非侵入性产前测试。章节还探讨了专利性的异常的构建和连贯性，在医学事物互联网背景下对FRAND许可的检查以及使用许可来鼓励或确保获得专利技术的道德使用的可能性。
通过精心构建的分析，本书将成为学术研究人员和学生在生物技术法，制药法和知识产权法领域的绝佳资源。这对于法律从业者和政策制定者以及慈善机构和非政府组织也将很有用。
Critical Acclaim
‘This fresh, timely collection examines the fundamental patent balance; that between private rights and access to innovation. In the context of biotechnology, the collection queries whether the patent system effectively protects the public interest in innovation and access to medical technology. The collection provides a truly international perspective by considering developments in the United States, European Union, United Kingdom, Australia and New Zealand. It will be of wide interest to scholars, policy-makers, students and non-government actors across many jurisdictions.’
- 澳大利亚堪培拉大学艾莉森·麦克伦南（Alison McLennan）
这是一个优秀的和令人兴奋的收集编辑ed by a highly respected scholar. It explores the always relevant and complex, and evolving, question of patenting biotechnological innovation and the public interest, and the extent to which the public interest is delivered. Dr Hawkins has led a team of the highest quality, with contributors from throughout the world exploring a valuable and innovative range of legal fields, perspectives, technologies and ethical questions. The conclusion, of the need for a multifaceted and coherent legal approach, is compelling.’
- 阿伯·布朗（Abbe Brown），英国阿伯丁大学
- 澳大利亚堪培拉大学艾莉森·麦克伦南（Alison McLennan）
这是一个优秀的和令人兴奋的收集编辑ed by a highly respected scholar. It explores the always relevant and complex, and evolving, question of patenting biotechnological innovation and the public interest, and the extent to which the public interest is delivered. Dr Hawkins has led a team of the highest quality, with contributors from throughout the world exploring a valuable and innovative range of legal fields, perspectives, technologies and ethical questions. The conclusion, of the need for a multifaceted and coherent legal approach, is compelling.’
- 阿伯·布朗（Abbe Brown），英国阿伯丁大学
贡献者
撰稿人：Mateo Aboy，Naomi Hawkins，Phoebe Li，Kathleen Liddell，Johnathon Liddicoat，Pheh Hoon Lim，Aisling McMahon，Dianne Nicol，Jane Nielsen，Jane Nielsen，Ella O’Sullivan，Alison Sagar，Alison Sagar，Alison Sagar，Karen Walsh，Karen Walsh
内容
内容:
1Introduction – patenting biotechnical innovation: in the
public interest? 1
Naomi Hawkins
2专利资格和精确医学：新兴
技术，法律通量和经验方法19
Andrew Sagar，Kathleen Liddell，Johnathon Liddicoat和Mateo Aboy
3非侵入性产前测试和弹性
patent system 43
Dianne Nicol and Jane Nielsen
4生物制造的人体器官的专利性：‘
自然”或“源自自然的产品”重新审视69
Pheh Hoon Lim and Phoebe Li
5 A problem of interpretation: is Article 53(a) EPC
necessarily restrictive of emerging technologies? 90
埃拉·奥沙利文（Ella O’Sullivan）
6援引欧洲专利系统的公共利益110
Karen Walsh
7重新定位获得医疗保健辩论的机会：弗兰德和
医学互联网137
Alison Slade
8在许可中考虑道德考虑
patented biotechnologies and health-related technologies:
理由164
麦克马洪
9专利和公共利益：一种多方面的方法197
Naomi Hawkins
指数
1Introduction – patenting biotechnical innovation: in the
public interest? 1
Naomi Hawkins
2专利资格和精确医学：新兴
技术，法律通量和经验方法19
Andrew Sagar，Kathleen Liddell，Johnathon Liddicoat和Mateo Aboy
3非侵入性产前测试和弹性
patent system 43
Dianne Nicol and Jane Nielsen
4生物制造的人体器官的专利性：‘
自然”或“源自自然的产品”重新审视69
Pheh Hoon Lim and Phoebe Li
5 A problem of interpretation: is Article 53(a) EPC
necessarily restrictive of emerging technologies? 90
埃拉·奥沙利文（Ella O’Sullivan）
6援引欧洲专利系统的公共利益110
Karen Walsh
7重新定位获得医疗保健辩论的机会：弗兰德和
医学互联网137
Alison Slade
8在许可中考虑道德考虑
patented biotechnologies and health-related technologies:
理由164
麦克马洪
9专利和公共利益：一种多方面的方法197
Naomi Hawkins
指数
